{
  "NCT05501665": {
    "verdict": "ELIGIBLE",
    "mode": "two_stage",
    "criteria": [
      {
        "text": "Age \\>= 18 years at time of informed consent",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient is a 43-year-old female, which satisfies the inclusion criterion requiring the patient to be at least 18 years of age.",
        "evidence_sentences": [
          1,
          16
        ],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient to be 18 years or older at the time of informed consent. This is an age requirement.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"A 43-year-old female presents...\" (Index 1) and \"The patient is a 43-year-old female.\" (Index 16).\n\n3.  Does the patient have the GENERAL condition described?\n    The general condition is being 18 years or older. The patient is 43 years old.\n    Answer: YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    The criterion specifies an age threshold (>= 18 years). The patient's age (43 years) meets this threshold.\n    Answer: SEVERITY MATCHES\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    The criterion specifies the age must be met \"at time of informed consent\". The note does not explicitly state when informed consent was obtained, but the patient is presenting for evaluation and treatment, implying informed consent is relevant to the current situation. The patient's age (43) is well above the threshold of 18.\n    Answer: MATCHES\n\n5.  How confident are you? HIGH"
      },
      {
        "text": "\u2022 Histologically documented or cytologically confirmed diagnosis of stage IVA or IVB (M1b or M1c) or locally advanced (not eligible for standard of care \\[SOC\\] chemoradiation) non-small cell lung cancer with evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient has histologically confirmed Stage IVA lung adenocarcinoma (NSCLC) with measurable disease per RECIST 1.1 (3.2 cm mass). The medical analysis confirms that the diagnosis and Stage IVA status meet the inclusion requirements.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires a histologically documented or cytologically confirmed diagnosis of stage IVA or IVB (M1b or M1c) or locally advanced non-small cell lung cancer (NSCLC) that is not eligible for standard of care (SOC) chemoradiation, with evaluable disease per RECIST v1.1 criteria. It specifies the cancer type (NSCLC), stage (IVA or IVB, or locally advanced), histological/cytological confirmation, ineligibility for SOC chemoradiation, and evaluable disease per RECIST v1.1.\n\n2.  What does the patient note explicitly state about this?\n    - \"Primary Diagnosis: Lung adenocarcinoma with signet-ring cell features\" (Index: Staging and Diagnosis) - This confirms NSCLC (adenocarcinoma).\n    - \"Stage: IVA (T2a N2 M1a per AJCC 8th edition) \u2014 based on bilateral pulmonary involvement, mediastinal lymph node metastases, and malignant pleural effusion\" (Index: Staging and Diagnosis) - This confirms Stage IVA NSCLC.\n    - \"Histopathologic analysis of tissue from all three right lung lobes and mediastinal lymph nodes confirmed malignancy...\" (Index: Assessment & Plan) - This confirms histological confirmation of malignancy.\n    - \"Imaging Findings... A large, well-circumscribed mass is present in the left lower lobe (3.2 cm, measurable per RECIST 1.1).\" (Index: Imaging Findings) - This indicates measurable disease per RECIST 1.1.\n    - \"Assessment: Stage IV lung adenocarcinoma...\" (Index: Assessment & Plan) - This reiterates the Stage IV diagnosis.\n\n3.  Does the patient have the GENERAL condition described?\n    YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE (e.g., mild, moderate, severe, early, advanced, Rutherford stage 2)?\n    YES, it specifies Stage IVA or IVB, or locally advanced.\n\n    Does the patient's documented condition match that specific level?\n    SEVERITY MATCHES\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    YES, it requires:\n    - Histologically documented or cytologically confirmed diagnosis: The note states \"Histopathologic analysis... confirmed malignancy\" (Index: Assessment & Plan).\n    - Stage IVA or IVB (M1b or M1c) or locally advanced: The note states \"Stage: IVA (T2a N2 M1a per AJCC 8th edition)\" (Index: Staging and Diagnosis). Stage IVA falls under the criterion's stage requirement.\n    - Not eligible for standard of care (SOC) chemoradiation: The note does not explicitly state ineligibility for SOC chemoradiation. However, Stage IV disease is generally considered metastatic and not typically treated with curative intent chemoradiation, although palliative radiation might be used. The criterion requires *ineligibility* for SOC chemoradiation. The note doesn't provide enough information to definitively determine eligibility/ineligibility for SOC chemoradiation. However, the criterion also includes locally advanced disease which *is* often treated with chemoradiation. The patient is Stage IVA (M1a), which is metastatic (Stage IV). Stage IV disease is generally not treated with SOC chemoradiation aimed at cure.\n    - Evaluable disease per RECIST v1.1 criteria: The note states \"A large, well-circumscribed mass is present in the left lower lobe (3.2 cm, measurable per RECIST 1.1).\" (Index: Imaging Findings). This indicates evaluable disease.\n\n    Does the patient match them?\n    MATCHES\n\n5.  How confident are you?\n    HIGH"
      },
      {
        "text": "Available tumor material (\\< 6 months old) adequate for confirmation of programmed cell death 1 ligand 1 (PD-L1) expression per local standard of care testing",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The medical analysis determines that the patient meets the inclusion criterion. The note documents recent histopathology and successful PD-L1 testing (TPS 60%), confirming the availability of adequate tumor material within the relevant timeframe.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  The criterion requires available tumor material less than 6 months old that is adequate for confirmation of PD-L1 expression testing according to local standards.\n\n2.  The patient note states: \"Histopathologic analysis of tissue from all three right lung lobes and mediastinal lymph nodes confirmed malignancy...\". This implies tumor tissue was obtained. The note does not explicitly state when the tissue was obtained, but the diagnosis and staging are based on current findings. The PD-L1 testing was performed on this tissue: \"PD-L1 TPS: 60% (by 22C3 pharmDx assay)\". The note does not specify the exact date of tissue acquisition relative to the PD-L1 testing, but the assessment is current. Given the recent diagnosis and testing, it is reasonable to assume the tissue is less than 6 months old and adequate for PD-L1 testing.\n\n3.  YES\n\n3b.  NO SEVERITY SPECIFIED\n\n4.  MATCHES\n\n5.  HIGH"
      },
      {
        "text": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient's ECOG performance status is recorded as 1, which falls within the required inclusion range of 0-2.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  The criterion requires an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. This is a measure of a patient's functional status, ranging from fully active (0) to completely disabled (5). The criterion specifies a range of 0 to 2, indicating a relatively good functional status.\n\n2.  The patient note explicitly states: \"ECOG Performance Status: 1 (ambulatory, able to carry out light work)\". This falls within the specified range of 0-2.\n\n3.  YES\n\n3b. SEVERITY MATCHES\n\n4.  N/A\n\n5.  HIGH"
      },
      {
        "text": "Adequate organ function to receive therapy as determined by investigators and other treating physicians",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient demonstrates adequate organ function through normal laboratory values (WBC, Hemoglobin, Platelets, Creatinine, LFTs, TSH) and an ECOG status of 1. Additionally, the clinical assessment explicitly states the patient is eligible for the first-line regimen, satisfying the requirement for adequate function as determined by treating physicians.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires adequate organ function to receive therapy. It does not specify which organ(s) or the specific type of therapy. It also does not specify a severity, staging, timing, or specificity requirement beyond \"adequate organ function\".\n\n2.  What does the patient note explicitly state about this?\n    The note provides laboratory values that are indicators of organ function:\n    - WBC: 7.2 \u00d7 10\u2079/L (normal)\n    - Hemoglobin: 12.8 g/dL (normal)\n    - Platelets: 245 \u00d7 10\u2079/L (normal)\n    - Creatinine: 0.8 mg/dL (normal; CrCl > 60 mL/min)\n    - AST/ALT: 22/18 U/L (normal)\n    - Total Bilirubin: 0.6 mg/dL (normal)\n    - TSH: 2.1 mIU/L (normal)\n    The note also states \"ECOG Performance Status: 1 (ambulatory, able to carry out light work)\", which is an indicator of general functional status, often related to organ function and disease burden. The assessment concludes the patient is \"Eligible for first-line immunotherapy-based regimen\". Eligibility for therapy often implies adequate organ function, although the specific criteria are not detailed in the note.\n\n3.  Does the patient have the GENERAL condition described?\n    The patient has normal WBC, Hemoglobin, Platelets, Creatinine (with CrCl > 60 mL/min), AST/ALT, Total Bilirubin, and TSH. The ECOG performance status is 1. These findings suggest adequate organ function.\n    Answer: YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    The criterion does not specify a particular severity, grade, or stage.\n    Answer: NO SEVERITY SPECIFIED\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    The criterion does not specify any additional qualifiers beyond \"adequate organ function\".\n    Answer: N/A\n\n5.  How confident are you?\n    Based on the normal laboratory values and ECOG performance status, the patient appears to have adequate organ function, which is a prerequisite for receiving therapy. The assessment explicitly states she is eligible for therapy.\n    Answer: HIGH"
      },
      {
        "text": "Participants with brain metastases that can be comprehensively managed with surgery and/or stereotactic radiosurgery, prior to initiation of chemo-immunotherapy are allowed. Number of brain metastases allowed is not specified at eligibility is at discretion of investigator",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "Patient has no brain metastases per brain MRI. This inclusion criterion is permissive (allows brain met patients), not restrictive. Verdict: MET.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires participants to have brain metastases that can be comprehensively managed with surgery and/or stereotactic radiosurgery, prior to initiation of chemo-immunotherapy. The number of brain metastases is not specified, and eligibility is at the discretion of the investigator.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"Brain MRI: No evidence of brain metastases.\" (Imaging Findings section)\n\n3.  Does the patient have the GENERAL condition described?\n    NO\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE (e.g., mild, moderate, severe, early, advanced, Rutherford stage 2)?\n    If so, does the patient's documented condition match that specific level?\n    N/A\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    If yes, does the patient match them?\n    N/A\n\n5.  How confident are you?\n    HIGH\n\n[CORRECTION] This criterion is a permissive clause allowing patients WITH stable brain metastases to participate. The patient has no brain metastases (brain MRI negative), so this criterion does not apply as a barrier. The patient meets this criterion by default."
      },
      {
        "text": "Contraceptive use should be initiated or continued per guidance in labeling for approved chemotherapies",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The criterion requires the initiation or continuation of contraceptive use. The medical analysis confirms the patient is a woman of childbearing potential using an intrauterine device (IUD), which qualifies as highly effective contraception. The analysis concludes YES and MATCHES, indicating the patient satisfies the inclusion requirement.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  The criterion requires that contraceptive use should be initiated or continued per guidance in labeling for approved chemotherapies. This applies to women of childbearing potential (WOCBP) receiving chemotherapy. The patient has Stage IV lung adenocarcinoma and is eligible for first-line immunotherapy-based regimen, which often involves chemotherapy agents.\n\n2.  The note states: \"The patient is a woman of childbearing potential (WOCBP). She is not currently pregnant (negative serum beta-hCG) and is not breastfeeding. She has an intrauterine device (IUD) in place as highly effective contraception.\" (Demographics section) and \"The patient is a 43-year-old female. Not pregnant, not breastfeeding. Using effective contraception (IUD).\" (Demographics section) and \"The patient is a woman of childbearing potential (WOCBP). She is not currently pregnant (negative serum beta-hCG) and is not breastfeeding. She has an intrauterine device (IUD) in place as highly effective contraception.\" (Reproductive Status section).\n\n3.  YES\n\n3b. NO SEVERITY SPECIFIED\n\n4.  MATCHES\n\n5.  HIGH"
      },
      {
        "text": "Female patients must be non-pregnant and not breastfeeding.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The medical analysis confirms that the patient satisfies the inclusion criterion. The analysis cites specific evidence from the note stating the patient is 'Not pregnant, not breastfeeding' and confirms a 'negative serum beta-hCG'. Since the analysis concludes YES and the evidence matches the requirement, the patient is eligible.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  The criterion requires female patients to be non-pregnant and not breastfeeding. This is a specific requirement for inclusion in certain studies or treatments, often related to reproductive health or potential fetal/infant harm from therapies.\n\n2.  The patient note explicitly states: \"Not pregnant, not breastfeeding.\" (Demographics section) and \"She is not currently pregnant (negative serum beta-hCG) and is not breastfeeding.\" (Reproductive Status section).\n\n3.  YES\n\n3b. NO SEVERITY SPECIFIED\n\n4.  N/A\n\n5.  HIGH"
      },
      {
        "text": "If woman of childbearing potential (WOCBP), must utilize highly effective contraceptive method (failure rate of \\< 1% per year) throughout intervention period and continued per guidance specified in labeling for approved chemotherapies. Must have negative pregnancy test (serum or urine) within 1 week prior to initiation of first cycle of therapy",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The analysis confirms the patient is a woman of childbearing potential who has a negative pregnancy test and is using an IUD (highly effective contraception), satisfying all conditions of the inclusion criterion.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  This criterion requires that a woman of childbearing potential (WOCBP) receiving chemotherapy must use a highly effective contraceptive method (failure rate < 1% per year) throughout the intervention period and continued per guidance specified in labeling for approved chemotherapies. She must also have a negative pregnancy test (serum or urine) within 1 week prior to initiating therapy.\n\n2.  The patient note states: \"The patient is a woman of childbearing potential (WOCBP). She is not currently pregnant (negative serum beta-hCG) and is not breastfeeding. She has an intrauterine device (IUD) in place as highly effective contraception.\" (Demographics section) and \"The patient is a 43-year-old female.\" (Demographics section).\n\n3.  YES\n\n3b. NO SEVERITY SPECIFIED\n\n4.  MATCHES\n\n5.  HIGH"
      },
      {
        "text": "Eligible for immunotherapy-based systemic regimens per judgment of patient's study physician",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The clinical note explicitly states that the patient is 'Eligible for first-line immunotherapy-based regimen' under the Assessment & Plan, which directly meets the inclusion criterion requiring eligibility for immunotherapy-based systemic regimens per the physician's judgment.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient to be eligible for immunotherapy-based systemic regimens based on the judgment of the patient's study physician. This implies the patient has a condition suitable for such treatment, likely advanced cancer, and meets specific criteria (e.g., PD-L1 expression, absence of certain mutations) that make immunotherapy a viable option. The note specifies Stage IVA lung adenocarcinoma, EGFR/ALK/ROS1 wild-type, and PD-L1 60%.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"Assessment: Stage IV lung adenocarcinoma, EGFR/ALK/ROS1 wild-type, PD-L1 60%. Eligible for first-line immunotherapy-based regimen.\" (Index: Assessment & Plan)\n\n3.  Does the patient have the GENERAL condition described?\n    The patient has Stage IV lung adenocarcinoma, which is a condition often treated with immunotherapy-based regimens. The note explicitly states she is eligible for such a regimen.\n    Answer: YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE (e.g., mild, moderate, severe, early, advanced, Rutherford stage 2)?\n    The criterion implies an advanced stage cancer suitable for systemic immunotherapy. The patient has Stage IVA (equivalent to Stage IV) lung adenocarcinoma.\n    Answer: SEVERITY MATCHES\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    The criterion requires eligibility for immunotherapy-based regimens. The note provides specific details supporting this eligibility: Stage IV disease, wild-type EGFR/ALK/ROS1, and high PD-L1 expression (60%). These are common factors considered for immunotherapy eligibility in non-small cell lung cancer.\n    Answer: MATCHES\n\n5.  How confident are you?\n    HIGH"
      }
    ]
  },
  "NCT05549037": {
    "verdict": "UNCERTAIN",
    "mode": "two_stage",
    "criteria": [
      {
        "text": "1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The medical analysis concludes that the patient note provides insufficient data regarding the patient's understanding of the trial requirements or the provision of signed informed consent. Following the mapping rules, a finding of insufficient data maps to the unknown label.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient to understand the requirements and contents of the clinical trial and provide a signed and dated informed consent form. This relates to the patient's ability to participate in a clinical trial, which requires informed consent. There are no severity, staging, timing, or specificity requirements related to a medical condition within the criterion itself, but rather a procedural requirement for trial participation. The underlying condition being checked is the patient's capacity to provide informed consent.\n\n2.  What does the patient note explicitly state about this?\n    The note does not explicitly state whether the patient understands the requirements and contents of a clinical trial or if she has provided a signed and dated informed consent form.\n\n3.  Does the patient have the GENERAL condition described?\n    The general condition described is the ability to provide informed consent for a clinical trial. The note does not provide information about whether the patient has been presented with a clinical trial, understands its requirements, or has provided consent. Therefore, we cannot determine if she meets this criterion based on the provided note.\n    Answer: INSUFFICIENT DATA\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    The criterion does not specify a severity, grade, or stage.\n    Answer: N/A\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    Since the answer to #3 is INSUFFICIENT DATA, this question is skipped.\n\n5.  How confident are you?\n    Answer: HIGH"
      },
      {
        "text": "2. Age \u2265 18 years.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient is explicitly stated to be a 43-year-old female, which satisfies the inclusion criterion of being 18 years of age or older.",
        "evidence_sentences": [
          1,
          33
        ],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient's age to be greater than or equal to 18 years.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"A 43-year-old female presents...\" (Index: 1) and \"The patient is a 43-year-old female.\" (Index: 33)\n\n3.  Does the patient have the GENERAL condition described?\n    The patient is 43 years old. The criterion requires age \u2265 18 years.\n    Answer: YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    No, the criterion only specifies an age threshold.\n    Answer: N/A\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    The criterion only specifies the age requirement (\u2265 18 years). The patient's age (43 years) meets this requirement.\n    Answer: MATCHES\n\n5.  How confident are you?\n    Answer: HIGH"
      },
      {
        "text": "3. Histopathology or cytology confirmed and recorded local progression or metastatic non-small cell lung cancer without systemic treatment.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient has Stage IVA lung adenocarcinoma, which is a form of metastatic non-small cell lung cancer (NSCLC). The condition is confirmed by histopathology, and the patient is explicitly documented as 'treatment-naive' with no prior systemic therapy. This satisfies all requirements of the inclusion criterion.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires histopathology or cytology confirmation of local progression or metastatic non-small cell lung cancer (NSCLC) without prior systemic treatment. It specifies NSCLC, confirmation via pathology/cytology, evidence of progression or metastasis, and absence of prior systemic treatment.\n\n2.  What does the patient note explicitly state about this?\n    - \"Primary Diagnosis: Lung adenocarcinoma with signet-ring cell features\" (Index: Staging and Diagnosis) - This confirms NSCLC (adenocarcinoma).\n    - \"Stage: IVA (T2a N2 M1a per AJCC 8th edition) \u2014 based on bilateral pulmonary involvement, mediastinal lymph node metastases, and malignant pleural effusion\" (Index: Staging and Diagnosis) - This indicates metastatic disease (M1a) and lymph node involvement (N2), representing progression/metastasis.\n    - \"Treatment History: Treatment-naive; no prior systemic therapy, radiation therapy, or surgical resection for lung cancer\" (Index: Staging and Diagnosis) - This confirms the absence of prior systemic treatment.\n    - \"Histopathologic analysis of tissue from all three right lung lobes and mediastinal lymph nodes confirmed malignancy...\" (Index: Assessment & Plan) - This confirms malignancy via histopathology.\n\n3.  Does the patient have the GENERAL condition described?\n    YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE (e.g., mild, moderate, severe, early, advanced, Rutherford stage 2)?\n    If so, does the patient's documented condition match that specific level?\n    The criterion requires metastatic or progressive NSCLC. The patient has Stage IVA NSCLC, which is metastatic.\n    Answer: SEVERITY MATCHES\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    - If yes, does the patient match them?\n      (subtype, timing/recency, threshold, modality)\n      Answer: MATCHES\n    The criterion requires histopathology or cytology confirmation. The note states \"Histopathologic analysis...confirmed malignancy\" (Index: Assessment & Plan). The criterion requires local progression or metastatic disease. The patient has Stage IVA (M1a), which is metastatic disease. The criterion requires no prior systemic treatment. The note states \"Treatment-naive; no prior systemic therapy\" (Index: Staging and Diagnosis). All specific qualifiers are met.\n\n5.  How confident are you?\n    HIGH"
      },
      {
        "text": "4. EGFR, ALK and ROS1 mutations negative confirmed by an accredited local laboratory.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The patient note explicitly confirms EGFR is 'Wild-type', ALK is 'Negative', and ROS1 is 'Negative', which satisfies the inclusion requirement for these mutations to be negative.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  The criterion requires confirmation that the patient's lung adenocarcinoma is negative for EGFR, ALK, and ROS1 mutations, confirmed by an accredited local laboratory.\n\n2.  The patient note states: \"EGFR: Wild-type (no activating mutations detected)\", \"ALK: Negative (no rearrangement by FISH)\", and \"ROS1: Negative (no rearrangement)\". It also states \"No confirmed oncogenic driver mutations\".\n\n3.  YES\n\n3b. NO SEVERITY SPECIFIED\n\n4.  MATCHES\n\n5.  HIGH"
      },
      {
        "text": "5. ECOG 0-1.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The inclusion criterion requires an ECOG performance status of 0 or 1. The medical analysis confirms the patient has a documented ECOG Performance Status of 1, which specifically matches the required range.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient to have an ECOG performance status of 0 or 1. This is a measure of functional status.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"ECOG Performance Status: 1 (ambulatory, able to carry out light work)\". (Index: Staging and Diagnosis)\n\n3.  Does the patient have the GENERAL condition described?\n    YES\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    If so, does the patient's documented condition match that specific level?\n    The criterion specifies an ECOG performance status of 0 or 1. The patient's documented ECOG performance status is 1.\n    Answer: SEVERITY MATCHES\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    If yes, does the patient match them?\n    The criterion specifies an ECOG score of 0 or 1. The patient's score is 1.\n    Answer: MATCHES\n\n5.  How confident are you?\n    HIGH"
      },
      {
        "text": "6. Predicted survival \u2265 12 weeks.",
        "type": "inclusion",
        "verdict": "UNKNOWN",
        "reasoning": "The criterion requires a predicted survival of at least 12 weeks. The analysis explicitly states that the patient note does not provide this specific prediction, concluding there is insufficient data to determine if the patient meets the requirement.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient to have a predicted survival of 12 weeks or greater. This is a measure of prognosis, specifically the expected duration of life.\n\n2.  What does the patient note explicitly state about this?\n    The patient note does not explicitly state the predicted survival duration. It provides information about the patient's diagnosis (Stage IV lung adenocarcinoma), performance status (ECOG 1), and biomarker status (EGFR/ALK/ROS1 wild-type, PD-L1 60%).\n\n3.  Does the patient have the GENERAL condition described?\n    The criterion refers to a predicted survival duration. The note does not provide this specific prediction. Therefore, we cannot determine if the patient meets this criterion based on the provided information.\n    Answer: INSUFFICIENT DATA\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    The criterion specifies a duration threshold (\u2265 12 weeks), which relates to the severity/prognosis of the condition.\n    Answer: N/A\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    Answer: N/A\n\n5.  How confident are you?\n    Answer: HIGH"
      },
      {
        "text": "7. Adequate bone marrow hematopoiesis and organ function",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The analysis indicates the patient has adequate bone marrow hematopoiesis and organ function, supported by specific normal laboratory values for WBC, Hemoglobin, Platelets, Creatinine, and liver enzymes. Since the patient satisfies this inclusion requirement, they are eligible.",
        "evidence_sentences": [
          2,
          3
        ],
        "stage1_reasoning": "1.  This criterion requires adequate bone marrow hematopoiesis and organ function. This implies the absence of significant hematologic abnormalities (like severe anemia, thrombocytopenia, or leukopenia) and organ dysfunction (like renal or hepatic failure) that would preclude treatment or indicate advanced disease affecting these systems. There are no specific severity, staging, timing, or specificity requirements mentioned beyond \"adequate\". The underlying conditions being checked are hematologic abnormalities and organ dysfunction.\n\n2.  The patient note states:\n    *   \"WBC: 7.2 \u00d7 10\u2079/L (normal)\" (Laboratory Values)\n    *   \"Hemoglobin: 12.8 g/dL (normal)\" (Laboratory Values)\n    *   \"Platelets: 245 \u00d7 10\u2079/L (normal)\" (Laboratory Values)\n    *   \"Creatinine: 0.8 mg/dL (normal; CrCl > 60 mL/min)\" (Laboratory Values)\n    *   \"AST/ALT: 22/18 U/L (normal)\" (Laboratory Values)\n    *   \"Total Bilirubin: 0.6 mg/dL (normal)\" (Laboratory Values)\n\n3.  YES\n\n3b. NO SEVERITY SPECIFIED\n\n4.  N/A\n\n5.  HIGH"
      },
      {
        "text": "8. Presence of measurable lesions according to RECIST 1.1.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "The analysis confirms the patient has a mass in the left lower lobe explicitly described as 'measurable per RECIST 1.1', which directly satisfies the inclusion criterion requiring the presence of measurable lesions.",
        "evidence_sentences": [
          2
        ],
        "stage1_reasoning": "1.  The criterion requires the presence of measurable lesions according to RECIST 1.1 criteria. RECIST 1.1 (Response Evaluation Criteria in Solid Tumors version 1.1) defines measurable lesions as those that can be accurately measured in at least one dimension (longest diameter) using conventional techniques (e.g., CT, MRI, chest X-ray). The criterion is specific to the presence of such lesions.\n\n2.  The note states: \"Additionally, there is evidence of interstitial changes in the right lung, including honeycombing and pleural thickening, particularly in the right lower lobe, along with a small right-sided pleural effusion.\" and \"A large, well-circumscribed mass is present in the left lower lobe (3.2 cm, measurable per RECIST 1.1).\"\n\n3.  YES\n\n3b. SEVERITY MATCHES\n\n4.  MATCHES\n\n5.  HIGH"
      },
      {
        "text": "9. Subjects with stable brain metastases may be included in the study.",
        "type": "inclusion",
        "verdict": "MET",
        "reasoning": "Patient has no brain metastases. Permissive clause does not restrict enrollment. Verdict: MET.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the subject to have stable brain metastases.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"Brain MRI: No evidence of brain metastases.\" (Imaging Findings section)\n\n3.  Does the patient have the GENERAL condition described?\n    NO\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE (e.g., mild, moderate, severe, early, advanced, Rutherford stage 2)?\n    If so, does the patient's documented condition match that specific level?\n    N/A\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    If yes, does the patient match them?\n    N/A\n    If NO to #3, skip this question.\n\n5.  How confident are you?\n    HIGH\n\n[CORRECTION] This is a permissive clause for brain metastasis patients. Patient has no brain metastases (brain MRI negative). Criterion met by default."
      },
      {
        "text": "1. Prior systemic therapy for locally advanced or metastatic disease.",
        "type": "exclusion",
        "verdict": "NOT_MET",
        "reasoning": "Patient is treatment-naive per clinical note. No prior systemic therapy. Exclusion does not apply. Verdict: NOT_MET.",
        "evidence_sentences": [],
        "stage1_reasoning": "1.  What does this criterion specifically require?\n    The criterion requires the patient to have had prior systemic therapy for locally advanced or metastatic disease. This refers to treatment given for cancer that has spread beyond the primary site (metastatic) or has spread to nearby lymph nodes or structures (locally advanced). The timing is prior to the current assessment.\n\n2.  What does the patient note explicitly state about this?\n    The note states: \"Treatment History: Treatment-naive; no prior systemic therapy, radiation therapy, or surgical resection for lung cancer\".\n\n3.  Does the patient have the GENERAL condition described?\n    The general condition is having received prior systemic therapy for locally advanced or metastatic disease. The note explicitly states the patient is treatment-naive and has had no prior systemic therapy.\n    Answer: NO\n\n3b. Does the criterion specify a particular SEVERITY, GRADE, or STAGE?\n    The criterion specifies the *type* of disease (locally advanced or metastatic) for which prior therapy might have been given, but not a specific severity, grade, or stage *of the prior therapy*.\n    Answer: N/A\n\n4.  If YES to #3: Does the criterion have additional SPECIFIC qualifiers beyond the general condition?\n    Since the patient does not have the general condition (prior systemic therapy), this question is skipped.\n\n5.  How confident are you? HIGH\n\n[CORRECTION] Patient is explicitly treatment-naive with no prior systemic therapy. The exclusion criterion for prior therapy does NOT apply."
      }
    ]
  }
}